## Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer’s disease in the EMIF-AD Multimodal Biomarker Discovery study

Rebecca G. Smith<sup>1</sup>, Jennifer Imm<sup>1</sup>, Valerija Dobricic<sup>2</sup>, Yasmine Sommerer<sup>2</sup>, Isabelle Bos<sup>3</sup>, Stephanie J. B. Vos<sup>4</sup>, Frans Verhey<sup>5</sup>, Philip Scheltens<sup>6</sup>, Sebastiaan Engelborghs<sup>7</sup>, Giovanni Frisoni<sup>8</sup>, Olivier Blin<sup>9</sup>, Jill Richardson<sup>10</sup>, Régis Bordet<sup>11</sup>, Magda Tsolaki<sup>12</sup>, Julius Popp<sup>13</sup>, Pablo Martinez-Lage<sup>14</sup>, Alberto Lleó<sup>15</sup>, Peter Johannsen<sup>16</sup>, Yvonne Freund-Levi<sup>17</sup>, Lutz Frölich<sup>18</sup>, Rik Vandenberghe<sup>19</sup>, Michael Wittig<sup>20</sup>, Andre Franke<sup>20</sup>, Simon Lovestone<sup>21</sup>, Johannes Streffer<sup>22</sup>, Ulf Andreasson<sup>23</sup>, Kaj Blennow<sup>24</sup>, Pieter Jelle Visser<sup>25</sup>, Henrik Zetterberg<sup>23</sup>, Lars Bertram<sup>2</sup> and Katie Lunnon<sup>1*</sup>

<ol>
  <li>Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, United Kingdom, </li>
  <li>Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany</li>
  <li>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands, </li>
  <li>Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands, </li>
  <li>Maastricht University Medical Center, Maastricht, Netherlands, </li>
  <li>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Amsterdam, Netherlands, </li>
  <li>Institute Born-Bunge, Antwerp, Belgium, </li>
  <li>On behalf of the AMYPAD consortium, Brussels, Belgium, </li>
  <li>Aix-Marseille University-CNRS, Marseille, France, </li>
  <li>GSK R&D, China-UK, Hertfordshire, United Kingdom, </li>
  <li>Université de Lille, Lille, France, </li>
  <li>Aristotle University of Thessaloniki, Thessaloniki, Greece, </li>
  <li>University Hospital of Psychiatry Zürich, Zürich, Switzerland, </li>
  <li>Fundación CITA-Alzhéimer Fundazioa, San Sebastian, Spain, </li>
  <li>Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain, </li>
  <li>Danish Dementia Research Centre, Rigshospitalet, Copenhagen, Denmark, </li>
  <li>Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden, </li>
  <li>Central Institute of Mental Health, Mannheim, Germany, </li>
  <li>Alzheimer Research Centre KU Leuven, Leuven Brain Institute, Leuven, Belgium, </li>
  <li>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany</li>
  <li>University of Oxford, Oxford, United Kingdom, </li>
  <li>UCB Biopharma SPRL, Brain-l'Alleud, Belgium,</li>
  <li>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden, </li>
  <li>Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden,</li>
  <li>Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands,</li>
</ol>
  
<sup>*</sup> Corresponding author: Katie Lunnon, University of Exeter Medical School, RILD, Barrack Road, University of Exeter, Devon, UK. UK. Tel: + 44 1392 408 298 Email address: k.lunnon@exeter.ac.uk

<p>INTRODUCTION: 
<br>The aim of this study was to identify DNA methylation signatures that were associated with 15 CSF biomarker measures of Alzheimer’s disease (AD) or neurodegeneration. </p>
<p>METHODS:
<br>We profiled DNA methylation in 886 blood samples from the EMIF-AD study using the Illumina EPIC array, identifying differentially methylated loci, and regions consisting of multiple adjacent differentially methylated sites. </p>
<p>RESULTS:
<br>We identified Bonferroni-significant differences in DNA methylation with respect to CSF t-tau Z-score (five loci), Aβ42 levels (one loci), YKL-40 levels (six loci) and NFL (seven loci). Significant differentially methylated regions were identified in 13 of the 15 analyses, with overlapping regions featuring in multiple CSF measures(MX2, RHOH, ANKMY1, ZFP57) analyses, which was unsurprising given the high correlation between measures. Interestingly, we identified several regions that overlapped between the tau and amyloid (ZBTB22), tau and NFL (S100A13), NFL and neurogranin (SORD), and neurogranin and amyloid (STRA6) regional analyses.</p>
<p>DISCUSSION:
<br>In this blood-based epigenome-wide association study of AD-relevant CSF biomarkers we identified several interesting genomic regions and classifiers, which can now be validated in future studies.</p>
